6 minute walk test in Duchenne MD patients with different mutations: 12 month changes

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Pane, Marika ^a   Mazzone, Elena S ^a   Sormani, Maria Pia ^b   Messina, Sonia ^c   Vita, Gian Luca ^c   Fanelli, Lavinia ^a   Berardinelli, Angela ^d   Torrente, Yvan ^e   D'Amico, Adele ^f   Lanzillotta, Valentina ^g   Viggiano, Emanuela ^h   D'Ambrosio, Paola ^h   Cavallaro, Filippo ^c   Frosini, Silvia ⁱ   Bello, Luca ^j   Bonfiglio, Serena ^k   Scalise, Roberta ^a   De Sanctis, Roberto ^a   Rolle, Enrica ^l   Bianco, Flaviana ^a   Van Der Haawue, Marlene ^m   Magri, Francesca ^e   Palermo, Concetta ^a   Rossi, Francesca ^m   Donati, Maria Alice ⁿ   Alfonsi, Chiara ^a   Sacchini, Michele ⁿ   Arnoldi, Maria Teresa ^o   Baranello, Giovanni ^o   Mongini, Tiziana ^l   Pini, Antonella ^k   Battini, Roberta ⁱ   Pegoraro, Elena ^j   Previtali, Stefano C ^p   Napolitano, Sara ^p   Bruno, Claudio ^g   Politano, Luisa ^h   Comi, Giacomo P ^e   Bertini, Enrico ^f   Morandi, Lucia ^o   Gualandi, Francesca ^q   Ferlini, Alessandra ^q   Goemans, Nathalie ^m   Mercuri, Eugenio ^a   more..

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^g G GASLINI INSTITUTE   (Italy)

^h SECOND UNIVERSITY OF NAPLES   (Italy)

ⁱ DEPARTMENT OF DEVELOPMENTAL NEUROSCIENCE   (Italy)

^j UNIVERSITY OF PADOVA   (Italy)

^k IRCCS ISTITUTO DELLE SCIENZE NEUROLOGICHE DI BOLOGNA   (Italy)

^l UNIVERSITY OF TURIN   (Italy)

^m UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁿ UNIVERSITY OF FLORENCE   (Italy)

^o DEPARTMENT OF NEUROSURGERY   (Italy)

^p SAN RAFFAELE HOSPITAL   (Italy)

^q UNIVERSITY OF FERRARA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

6 MINUTE WALK TEST; ADOLESCENT; ARTICLE; CHILD; COHORT ANALYSIS; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; FUNCTION TEST; GENE DELETION; GENE DUPLICATION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POINT MUTATION; WALKING;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DYSTROPHIN; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; TIME FACTORS; WALKING;

EID: 84897449030     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083400     Document Type: Article

References (26)

1. Laing NG, Davis MR, Bayley K, Fletcher S, Wilton SD (2011) Molecular diagnosis of duchenne muscular dystrophy: past, present and future in relation to implementing therapies. Clin Biochem Rev 32: 129-134.
2. Aartsma-Rus A, den Dunnen JT, van Ommen GJ (2010) New insights in gene-derived therapy: the example of Duchenne muscular dystrophy. Ann N Y Acad Sci 1214: 199-212.
3. Muntoni F, Wood MJ (2011) Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov 10: 621-637.
4. Foster H, Popplewell L, Dickson G (2012) Genetic therapeutic approaches for Duchenne muscular dystrophy. Hum Gene Ther 23: 676-687.
5. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357: 2677-2686.
6. van Ommen GJ, van Deutekom J, Aartsma-Rus A (2008) The therapeutic potential of antisense-mediated exon skipping. Curr Opin Mol Ther 10: 140-149.
7. Aartsma-Rus A (2012) Overview on DMD exon skipping. Methods Mol Biol 867: 97-116.
8. Arechavala-Gomeza V, Anthony K, Morgan J, Muntoni F (2012) Antisense oligonucleotide-mediated exon skipping for duchenne muscular dystrophy: progress and challenges. Curr Gene Ther 12: 152-160.
9. Muntoni F (2010) The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009. Neuromuscul Disord 20: 355-362.
10. Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378: 595-605.
11. Cirak S, Feng L, Anthony K, Arechavala-Gomeza V, Torelli S, et al. (2012) Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol Ther 20: 462-467.
12. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, et al. (2011) Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364: 1513-1522.
13. van Deutekom JC, van Ommen GJ (2003) Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet 4: 774-783.
14. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, et al. (2010) The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 41: 500-510.
15. Mazzone E, Vasco G, Sormani MP, Torrente Y, Berardinelli A, et al. (2011) Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 77: 250-256.
16. Mazzone ES, Pane M, Sormani MP, Scalise R, Berardinelli A, et al. (2013) 24 month longitudinal data in ambulant boys with duchenne muscular dystrophy. PLoS One 8: e52512.
17. (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166: 111-117.
18. Henricson E, Abresch R, Han JJ, Nicorici A, Goude Keller E, et al. (2012) Percent-predicted 6-minute walk distance in duchenne muscular dystrophy to account for maturational influences. PLoS Curr 4: RRN1297.
19. Geiger R, Strasak A, Treml B, Gasser K, Kleinsasser A, et al. (2007) Six-minute walk test in children and adolescents. J Pediatr 150: 395-399, 399 e391-392.
20. Magri F, Govoni A, D'Angelo MG, Del Bo R, Ghezzi S, et al. (2011) Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. J Neurol 258: 1610-1623.
21. Kesari A, Pirra LN, Bremadesam L, McIntyre O, Gordon E, et al. (2008) Integrated DNA, cDNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule. Hum Mutat 29: 728-737. (Pubitemid 351614598)
22. Deburgrave N, Daoud F, Llense S, Barbot JC, Recan D, et al. (2007) Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene. Hum Mutat 28: 183-195. (Pubitemid 46233316)
23. Lourbakos A, Sipkens J, Beekman C, Kreuger D, Brasz L, et al. (2011) The incidence of revertant and trace dystrophin expression in muscle biopsies of Duchenne Muscular Dystrophy patients with different exon deletions. Neuromuscul Disord 21: 643-643.
24. Pegoraro E, Hoffman EP, Piva L, Gavassini BF, Cagnin S, et al. (2011) SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 76: 219-226.
25. Flanigan KM, Ceco E, Lamar KM, Kaminoh Y, Dunn DM, et al. (2012) LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy. Ann Neurol.2013 e pub only
26. McDonald CM, Henricson EK, Abresch RT, Florence J, Eagle M, et al. (2013) The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 48: 343-356.